|1.||Mohler, Peter J: 30 articles (02/2015 - 02/2003)|
|2.||Geppetti, Pierangelo: 15 articles (07/2015 - 01/2010)|
|3.||Hund, Thomas J: 14 articles (02/2015 - 10/2008)|
|4.||Bennett, Vann: 13 articles (08/2015 - 02/2003)|
|5.||Nassini, Romina: 13 articles (07/2015 - 01/2010)|
|6.||Materazzi, Serena: 12 articles (07/2015 - 01/2010)|
|7.||Gallagher, Patrick G: 8 articles (03/2011 - 09/2005)|
|8.||Fusi, Camilla: 7 articles (07/2015 - 01/2012)|
|9.||Patacchini, Riccardo: 6 articles (07/2015 - 01/2010)|
|10.||Trevisan, Gabriela: 6 articles (01/2015 - 08/2013)|
|1.||Acute Erythroblastic Leukemia (Erythroleukemia)
01/01/2015 - "Inclusion of a single copy of the Ankyrin insulator did not affect viral titer, and improved the consistency of expression from the vector in murine erythroleukemia cells. "
05/01/1993 - "After the onset of band 3 expression in human erythroleukemia cells, an increase of membrane-associated fluorescence was detectable for both ankyrin and spectrin, supporting the general view that band 3 promotes assembly of the membrane cytoskeleton. "
05/01/1993 - "Different sequences of expression of band 3, spectrin, and ankyrin during normal erythropoiesis and erythroleukemia."
05/01/1993 - "These findings indicate that the current concept of a sequential expression of spectrin/ankyrin and band 3 is valid only for erythroleukemia cells or transformed erythropoietic cell lines but does not occur in normal erythropoiesis, during which these proteins become expressed simultaneously."
05/01/1993 - "Expression of the erythrocyte anion exchanger band 3, and ankyrin and spectrin, two cytoskeletal proteins of the red blood cell membrane, was studied by immunofluorescence using: 1) smears of human bone marrow from healthy donors and from a patient with erythroleukemia, 2) human red blood cell precursors grown in cell culture, and 3) murine erythroleukemia cells grown in cell culture. "
09/25/1991 - "Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis."
06/01/1986 - "Most importantly, in intact lymphoma cells this ankyrin-like protein is localized directly underneath the plasma membrane and is found to be preferentially accumulated beneath receptor cap structures as well as associated with a membrane-cytoskeleton complex preparation. "
06/01/1986 - "A lymphoma plasma membrane-associated protein with ankyrin-like properties."
12/15/1993 - "The purposes of this study are to characterize the binding of hyaluronic acid (HA) to mouse T lymphoma cells, to measure changes in intracellular Ca2+ after HA binding, to elucidate the interaction between the HA receptor, GP85(CD44), and ankyrin in the membrane skeleton, and finally to correlate these events with HA receptor patching/capping and cell adhesion to HA. "
09/25/1991 - "In this study, we have investigated the biosynthesis and processing of GP85 (Pgp-1/CD44), a lymphoma transmembrane glycoprotein known to contain ankyrin-binding site(s). "
03/01/2011 - "We previously identified a mutation in the human Ankyrin-1 (ANK-1) promoter that causes the disease ankyrin-deficient Hereditary Spherocytosis (HS). "
02/01/2011 - "A new ankyrin mutation (ANK1 EXON E9X) causing severe hereditary spherocytosis in the neonatal period."
07/01/2010 - "We previously identified a dinucleotide deletion in the human ankyrin-1 gene (ANK-1) promoter that underlies ankyrin-deficient hereditary spherocytosis. "
10/01/2008 - "Ankyrin-linked hereditary spherocytosis in an African-American kindred."
06/15/2007 - "Defects in erythrocyte ankyrin are the most common cause of typical, dominant hereditary spherocytosis (HS). "
05/01/2000 - "In this study, we focused on the functional domain in ankyrin (in particular, the ankyrin repeat domain [ARD]) responsible for CD44 binding and its role in regulating HA-mediated ovarian tumor cell function. "
01/01/1998 - "To study the role of CD44s-ankyrin interaction in regulating human prostate tumor cells, we have constructed several CD44s cytoplasmic deletion mutants that lack the ankyrin-binding site(s). "
05/19/2011 - "POTE ankyrin domain family, member H (POTEH) belongs to POTE family, which expresses in many cancers. "
08/01/2008 - "This article reviews the current evidence for HA/CD44-mediated activation of the ankyrin-based cytoskeleton and RhoGTPase signaling during tumor progression. "
06/20/2008 - "Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells."
|5.||Bipolar Disorder (Mania)
04/01/2015 - "Polymorphisms at the rs10994336 and rs9804190 loci of the Ankyrin 3 (ANK3) gene have been strongly associated with increased risk for bipolar disorder (BD). "
04/01/2014 - "Genetic variants within the ankyrin 3 gene (ANK3) have been identified as a risk factor for bipolar disorder. "
08/01/2013 - "Several genome-wide association studies for bipolar disorder (BD) have found a strong association of the Ankyrin 3 (ANK3) gene. "
04/01/2013 - "Ankyrin 3 (ANK3) has been strongly implicated as a risk gene for bipolar disorder (BD) by recent genome-wide association studies of patient populations. "
12/01/2012 - "Genome-wide association studies (GWAS) recently identified ankyrin 3 (ANK3) as a candidate gene for bipolar disorder type I (BPD-I). "
|1.||Proteins (Proteins, Gene)
|2.||Calcium Channels (Calcium Channel)
|4.||DNA (Deoxyribonucleic Acid)
|5.||Ion Channels (Ion Channel)
|6.||Membrane Proteins (Integral Membrane Proteins)
|7.||Protein Isoforms (Isoforms)
|8.||Hyaluronic Acid (Hyaluronan)
|9.||Inositol 1,4,5-Trisphosphate Receptors (Inositol Triphosphate Receptor)
|1.||Drug Therapy (Chemotherapy)